|Bid||39.66 x 800|
|Ask||39.73 x 1200|
|Day's Range||39.20 - 40.39|
|52 Week Range||33.39 - 64.22|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 11, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||53.33|
One of the dangers of investing right now is that there are many high-priced stocks out there. GoodRx's business makes it easier for consumers to buy prescriptions at lower prices. GoodRx's lack of an edge is especially concerning given one of its competitors may end up being Amazon (NASDAQ: AMZN).
Goodrx (NASDAQ: GDRX) recently released its list of the 10 most expensive drugs on the market. Novartis' (NYSE: NVS) gene therapy Zolgensma remains at the top, but newcomers Eiger Pharmaceuticals (NASDAQ: EIGR) and Y-mAbs Therapeutics (NASDAQ: YMAB) took second and third place with Zokinvy and Danyelza, respectively. In this video from Motley Fool Live, recorded on March 15, Fool.com Contributors Brian Orelli and Keith Speights discuss the high-priced drugs and whether the prices are sustainable in the long run.
The COVID-19 pandemic produced a growth slowdown at pharmaceutical drug discounter GoodRx Holdings (NASDAQ: GDRX). The increase in physical distancing also blunted the flu season, which further reduced the need for medications. In this video from Motley Fool Live, recorded on March 15, Fool.com Contributors Brian Orelli and Keith Speights discuss what outside factors could help GoodRx accelerate growth in the quarters to come.